获取途径

作者

Hongsheng Li Yanli Hou Wenyong Xin Lina Ding Ying Yang Yikun Zhang Wenqi Wu Zhibin Wang Wenyu Ding

作者单位

¹Endocrine and Metabolic Diseases Hospital of Shandong First Medical University, Shandong First Medical University & Shandong Academy of Medical Sciences, 18877, Jingshi Rd, Jinan 250062, China ³Shandong Institute of Endocrine and Metabolic Diseases, 18877, Jingshi Rd, Jinan 250062, China ²Jinan Key Laboratory of Translational Medicine on Metabolic Diseases, 18877, Jingshi Rd, Jinan 250062, China ⁴Department of Retirement Affairs, Shandong First Medical University & Shandong Academy of Medical Sciences, 18877, Jingshi Rd, Jinan 250062, China

刊名

Pharmacological Research

年份

2025

卷号

Vol.213

页码

107647

ISSN

1043-6618

关键词

Sodium-glucose transporter 2 inhibitors Nonalcoholic fatty liver disease Liver enzymes Meta-analysis

摘要

The efficacy of sodium-glucose transporter 2 inhibitors for nonalcoholic fatty liver disease is unclear. Therefore, we conducted a systematic review and meta-analysis to evaluate SGLT-2 inhibitors efficacy for NAFLD treatment. We systematically searched major electronic databases from inception until 11/2023, identifying randomized controlled trials of SGLT-2 inhibitors treatment for patients with NAFLD. The mean differences and 95 % confidence intervals were calculated via random-effects ...更多

The efficacy of sodium-glucose transporter 2 inhibitors for nonalcoholic fatty liver disease is unclear. Therefore, we conducted a systematic review and meta-analysis to evaluate SGLT-2 inhibitors efficacy for NAFLD treatment. We systematically searched major electronic databases from inception until 11/2023, identifying randomized controlled trials of SGLT-2 inhibitors treatment for patients with NAFLD. The mean differences and 95 % confidence intervals were calculated via random-effects models. Eleven articles were included in this study. Of these, 408 participants received SGLT-2 inhibitors, while 397 participants were in the control group. SGLT-2 inhibitors significantly reduced liver enzyme levels, including aspartate alanine aminotransferase and improvements in glycaemic indices, triglyceride and high-density lipoprotein cholesterol . However, no significant changes in total cholesterol or low-density lipoprotein cholesterol were observed. The meta-analysis revealed a beneficial effect of SGLT-2 inhibitors on liver functions and body weight, BMI, TG, HDL-C, and glucose homeostasis in patients with NAFLD, indicating that SGLT-2 inhibitors might be a clinical therapeutic strategy for these patients, especially individuals with concurrent type 2 diabetes mellitus .收起

文献类型

期刊